期刊
LANCET
卷 389, 期 10082, 页码 1931-1940出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(17)31222-9
关键词
-
资金
- AstraZeneca
- Takeda
- Chiesi
- Novartis
- Boehringer Ingelheim
- Sanofi Aventis
- Berlin Chemie
- Teva
- GlaxoSmithKline
- AstraZeneca
- Takeda
- Chiesi
- Novartis
- Boehringer Ingelheim
- Sanofi Aventis
- Berlin Chemie
- Teva
- GlaxoSmithKline
Chronic obstructive pulmonary disease (COPD) kills more than 3 million people worldwide every year. Despite progress in the treatment of symptoms and prevention of acute exacerbations, few advances have been made to ameliorate disease progression or affect mortality. A better understanding of the complex disease mechanisms resulting in COPD is needed. Smoking cessation programmes, increasing physical activity, and early detection and treatment of comorbidities are further key components to reduce the burden of the disease. However, without a global political and economic effort to reduce tobacco use, to regulate environmental exposure, and to find alternatives to the massive use of biomass fuel, COPD will remain a major health-care problem for decades to come.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据